Actively Recruiting
General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to COVID-19
Led by Weill Medical College of Cornell University · Updated on 2025-08-03
120
Participants Needed
1
Research Sites
323 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
It is expected that large numbers of healthcare workers will experience a broad range of psychological reactions and symptoms including anxiety, depression, moral distress, and trauma symptoms that will cause both significant suffering as well as occupational and social impairment. The purpose of this study is to find interventions which are helpful in treating psychological distress in healthcare workers caring for COVID-19 patients. There are two phases of the study. All participants will take part in Phase I, which consists of 4 sessions over a two-week period of either a narrative writing intervention or a medical music intervention. Participants will be randomly assigned to the narrative writing intervention or medical music intervention. After Phase I, participants will be re-assessed. Healthcare workers who meet criteria for PTSD will be given the option to participate in Phase II of the study, in which they will be offered a choice between one of two evidence-based treatments for PTSD: Interpersonal Therapy (IPT) or Exposure Therapy (ET). Both treatments are comprised of ten 75-minute sessions scheduled twice weekly. Participants will be allowed to choose a preferred treatment in Phase II. After Phase II participants will complete a final assessment concluding the study. All interventions will be offered using distance technology.
CONDITIONS
Official Title
General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to COVID-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthcare workers providing medical care or support for COVID-19 patients
- English-speaking
- Age over 18 years
- Medically stable
- Able to provide informed consent and complete assessments accurately
- If on psychotropic medication, doses stable for at least 60 days
- For Phase II: current diagnosis of PTSD
You will not qualify if you...
- Unstable medical illness that prevents regular session attendance or assessment completion
- Current risk of harm to self or others as judged by investigator
- Lifetime or current diagnosis of schizophrenia or other psychotic disorder
- Participation in a clinical trial or evidence-based psychiatric treatment, including for PTSD, within the past 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Weill Cornell Medicine
New York, New York, United States, 10065
Actively Recruiting
Research Team
O
Olivia Baryluk, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here